Linked Life Data

17869387

Source:http://linkedlifedata.com/resource/pubmed/id/17869387

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:17869387rdf:typepubmed:Citationlld:pubmed
pubmed-article:17869387lifeskim:mentionsumls-concept:C2304069lld:lifeskim
pubmed-article:17869387lifeskim:mentionsumls-concept:C0031727lld:lifeskim
pubmed-article:17869387lifeskim:mentionsumls-concept:C1155874lld:lifeskim
pubmed-article:17869387lifeskim:mentionsumls-concept:C0220781lld:lifeskim
pubmed-article:17869387lifeskim:mentionsumls-concept:C1332753lld:lifeskim
pubmed-article:17869387lifeskim:mentionsumls-concept:C1421500lld:lifeskim
pubmed-article:17869387lifeskim:mentionsumls-concept:C0038477lld:lifeskim
pubmed-article:17869387lifeskim:mentionsumls-concept:C1883254lld:lifeskim
pubmed-article:17869387lifeskim:mentionsumls-concept:C0243071lld:lifeskim
pubmed-article:17869387lifeskim:mentionsumls-concept:C0243077lld:lifeskim
pubmed-article:17869387lifeskim:mentionsumls-concept:C1004514lld:lifeskim
pubmed-article:17869387pubmed:issue6lld:pubmed
pubmed-article:17869387pubmed:dateCreated2008-6-2lld:pubmed
pubmed-article:17869387pubmed:abstractTextA series of N-6 substituted 9-hydroxy-4-phenylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-diones were prepared from N-substituted (5-methoxyphenyl)ethenylindoles. The target compounds were tested for their ability to inhibit the G2/M cell cycle checkpoint kinases, Wee1 and Chk1. Analogues with neutral or cationic N-6 side chains were potent dual inhibitors. Acidic side chains provided potent (average IC(50) 0.057 microM) and selective (average ratio 223-fold) Wee1 inhibition. Co-crystal structures of inhibitors bound to Wee1 show that the pyrrolo[3,4-c]carbazole scaffold binds in the ATP-binding site, with N-6 substituents involved in H-bonding to conserved water molecules. HT-29 cells treated with doxorubicin and then target compounds demonstrate an active Cdc2/cyclin B complex, inhibition of the doxorubicin-induced phosphorylation of tyrosine 15 of Cdc2 and abrogation of the G2 checkpoint.lld:pubmed
pubmed-article:17869387pubmed:languageenglld:pubmed
pubmed-article:17869387pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17869387pubmed:citationSubsetIMlld:pubmed
pubmed-article:17869387pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17869387pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17869387pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17869387pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17869387pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17869387pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17869387pubmed:statusMEDLINElld:pubmed
pubmed-article:17869387pubmed:monthJunlld:pubmed
pubmed-article:17869387pubmed:issn0223-5234lld:pubmed
pubmed-article:17869387pubmed:authorpubmed-author:DennyWilliam...lld:pubmed
pubmed-article:17869387pubmed:authorpubmed-author:LunneyElizabe...lld:pubmed
pubmed-article:17869387pubmed:authorpubmed-author:KrakerAlan...lld:pubmed
pubmed-article:17869387pubmed:authorpubmed-author:BakerEdward...lld:pubmed
pubmed-article:17869387pubmed:authorpubmed-author:PalmerBrian...lld:pubmed
pubmed-article:17869387pubmed:authorpubmed-author:SquireChristo...lld:pubmed
pubmed-article:17869387pubmed:authorpubmed-author:BridgesAlexan...lld:pubmed
pubmed-article:17869387pubmed:authorpubmed-author:SmaillJeff...lld:pubmed
pubmed-article:17869387pubmed:authorpubmed-author:DobrusinEllen...lld:pubmed
pubmed-article:17869387pubmed:authorpubmed-author:QuinJohnJ3rdlld:pubmed
pubmed-article:17869387pubmed:authorpubmed-author:BoothR JohnRJlld:pubmed
pubmed-article:17869387pubmed:authorpubmed-author:DicksonJames...lld:pubmed
pubmed-article:17869387pubmed:authorpubmed-author:IvanovicIvanIlld:pubmed
pubmed-article:17869387pubmed:authorpubmed-author:ThompsonAndre...lld:pubmed
pubmed-article:17869387pubmed:authorpubmed-author:LeeHo HHHlld:pubmed
pubmed-article:17869387pubmed:authorpubmed-author:OrtwineDaniel...lld:pubmed
pubmed-article:17869387pubmed:issnTypePrintlld:pubmed
pubmed-article:17869387pubmed:volume43lld:pubmed
pubmed-article:17869387pubmed:ownerNLMlld:pubmed
pubmed-article:17869387pubmed:authorsCompleteYlld:pubmed
pubmed-article:17869387pubmed:pagination1276-96lld:pubmed
pubmed-article:17869387pubmed:dateRevised2009-11-19lld:pubmed
pubmed-article:17869387pubmed:meshHeadingpubmed-meshheading:17869387...lld:pubmed
pubmed-article:17869387pubmed:meshHeadingpubmed-meshheading:17869387...lld:pubmed
pubmed-article:17869387pubmed:meshHeadingpubmed-meshheading:17869387...lld:pubmed
pubmed-article:17869387pubmed:meshHeadingpubmed-meshheading:17869387...lld:pubmed
pubmed-article:17869387pubmed:meshHeadingpubmed-meshheading:17869387...lld:pubmed
pubmed-article:17869387pubmed:meshHeadingpubmed-meshheading:17869387...lld:pubmed
pubmed-article:17869387pubmed:meshHeadingpubmed-meshheading:17869387...lld:pubmed
pubmed-article:17869387pubmed:meshHeadingpubmed-meshheading:17869387...lld:pubmed
pubmed-article:17869387pubmed:meshHeadingpubmed-meshheading:17869387...lld:pubmed
pubmed-article:17869387pubmed:meshHeadingpubmed-meshheading:17869387...lld:pubmed
pubmed-article:17869387pubmed:year2008lld:pubmed
pubmed-article:17869387pubmed:articleTitleSynthesis and structure-activity relationships of N-6 substituted analogues of 9-hydroxy-4-phenylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-diones as inhibitors of Wee1 and Chk1 checkpoint kinases.lld:pubmed
pubmed-article:17869387pubmed:affiliationAuckland Cancer Society Research Centre, School of Medical Sciences, The University of Auckland, Private Bag 92019, Auckland 1020, New Zealand. j.smaill@auckland.ac.nzlld:pubmed
pubmed-article:17869387pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:17869387pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...http://linkedlifedata.com/r...pubmed-article:17869387lld:chembl
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17869387lld:pubmed